1262297-38-0

Upstream product

• 10521-06-9 oxonane-2,9-dione 
• 619-45-4 4-methoxycarbonyl aniline 

Downstream Products

• 149648-10-2 C₁₆H₂₂N₂O₅ 
• 1262297-32-4 4-(8-(Hydroxyamino)-8-oxooctanamido)benzoic Acid 
• 1609087-57-1 C₂₃H₂₈N₂O₅ 
• 1609087-56-0 N¹-(4-((3-Aminopyridin-4-yl)carbamoyl)phenyl)-N⁸-hydroxyoctanediamide 
• 1609087-55-9 N¹-(4-((2-aminopyridin-3-yl)carbamoyl)phenyl)-N⁸-hydroxyoctanediamide 
• 1609087-54-8 N¹-(4-((2-aminophenyl)carbamoyl)phenyl)-N⁸-hydroxyoctanediamide 
• 1609087-53-7 C₂₇H₃₁N₅O₄ 
• 1609087-52-6 C₂₇H₃₁N₅O₄ 
• 1609087-51-5 C₂₈H₃₂N₄O₄ 

Relevant academic research and scientific papers

Novel polyamine-based Histone deacetylases-Lysine demethylase 1 dual binding inhibitors

Epigenetic modulators Histone deacetylases (HDACs) and Lysine demethylase (LSD1) are validated targets for anticancer therapy. Both HDAC1/2 and LSD1 are found in association with the repressor protein CoREST in a transcriptional co-repressor complex, whic

METAL COMPLEXES HAVING DUAL HISTONE DEACETYLASE INHIBITORY AND DNA-BINDING ACTIVITY

Compounds comprising a metal complex having the structure [X-Y-Z-Mn+]p+. B are disclosed in which X is a histone deacetylase inhibitor, Mn+ is a DNA -binding heavy metal ion, Y is an aliphatic or aromatic spacer or is absent, and Z is a mono- or bi-dentate or chelating donor linker, or a bridging linker, P+ designates the charge on the complex ion, which may be positive, negative or absent and B is a counterion or is absent. The linker Z is labile and its metal complex X-Y-Z-Mn+ is capable of being hydrolysed in-vivo. The compounds find application in the treatment of cancer.